WO2012005379A1 - Transformant obtenu par introduction d'un gène gm1 et d'un gène crmp2 - Google Patents

Transformant obtenu par introduction d'un gène gm1 et d'un gène crmp2 Download PDF

Info

Publication number
WO2012005379A1
WO2012005379A1 PCT/JP2011/065918 JP2011065918W WO2012005379A1 WO 2012005379 A1 WO2012005379 A1 WO 2012005379A1 JP 2011065918 W JP2011065918 W JP 2011065918W WO 2012005379 A1 WO2012005379 A1 WO 2012005379A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
crmp2
transformant
cells
amino acid
Prior art date
Application number
PCT/JP2011/065918
Other languages
English (en)
Japanese (ja)
Inventor
康彦 高橋
正樹 片岡
Original Assignee
住友化学株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 住友化学株式会社 filed Critical 住友化学株式会社
Publication of WO2012005379A1 publication Critical patent/WO2012005379A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the present invention relates to a transformant into which a Gm1 gene and a CRMP2 gene have been introduced and use thereof.
  • Gm1 protein is a kind of G-protein ⁇ subunit, and is known to be involved in intracellular signal transduction by G-protein coupled receptor (GPCR) stimulation.
  • GPCR G-protein coupled receptor
  • the Gm1 gene is a Splicing variant of the Golf gene, and has a unique base sequence only in the first exon region, and shares the base sequence with the Golf gene after the second exon region.
  • the Gm1 protein is a kind of G-protein ⁇ subunit represented by the registration number “NM — 182978” in the NCBI database.
  • the N-terminal region has a characteristic structure that is about 80 amino acids longer than other G proteins (see, for example, US2005-0260595).
  • the CRMP2 protein is a collapse response mediator protein 2 (Collapsin Response Mediator Protein 2, CRMP2), which is a protein identified as a factor that mediates information on semaphorin, which is a nerve guidance factor (eg, Nature (1995), 376). , 509-514).
  • CRMP2 protein has a function of extending axon by directly or indirectly binding to molecules such as tubulin, Numb, Sra-1, TrkB, and transporting these molecules to the axon tip.
  • a kinase such as cdk5, GSK3 ⁇ , Rho kinase, etc.
  • non-phosphorylated form has activity and is phosphorylated by kinase It is known that it is inactivated (Cell, 120, 137-149, (2005), Mol. Cell. Biol., 25, 9973-9984 (2005)). It has also been reported that introduction of a non-phosphorylated mutant CRMP2 gene into neurons impairs the axon retraction, and inhibition of CRMP2 protein biological function in neurons inhibits axon elongation. (Cell, 120, 137-149, (2005), J. Biol. Chem., 275, 2397-23980 (2000)). Overexpression of CRMP2 protein after nerve injury promotes nerve axon regeneration (eg, J. Neurochem., 86, 1042-50, (2003)), and CRMP2 protein mutation is a risk factor for schizophrenia (For example, Biol Psychiatry., 53, 571-576, (2003)) has been reported.
  • the present invention is based on the newly discovered finding that activation of the biological function of Gm1 protein suppresses phosphorylation of CRMP2 protein, that is, the biological function of CRMP2 protein is activated. . That is, the present invention is 1.
  • a transformant in which both of the following genes (1) and (2) are introduced into a host cell (hereinafter sometimes referred to as the transformant of the present invention): (1) a foreign gene having a base sequence encoding the amino acid sequence of Gm1 protein, and (2) a foreign gene having a base sequence encoding the amino acid sequence of CRMP2 protein; 2. [2] The transformant according to [1] above, wherein the foreign gene is a nucleic acid in the form of a plasmid containing a base sequence encoding the amino acid sequence of the protein; 3. 3. The transformant according to item 1 or 2, wherein both of the proteins encoded by the genes (1) and (2) are co-expressed in the cells; 4).
  • A a first step of bringing a test substance into contact with the transformant according to the preceding item 1, 2, or 3,
  • B a second step of measuring the phosphorylation state of CRMP2 protein in the transformant after the first step or an index value correlated therewith;
  • C a test substance that varies the phosphorylation state of CRMP2 protein in the transformant or the index value correlated therewith by comparing the phosphorylation state measured in the second step or the index value correlated therewith with a control.
  • a screening method for a substance that regulates signal transduction via Gm1 protein, which comprises a third step to be selected (hereinafter also referred to as the screening method of the present invention); 5. 4.
  • a substance that regulates signal transduction via Gm1 protein obtained by the screening method according to 4 or 5 above; 7.
  • a therapeutic or prophylactic agent for diseases caused by abnormal signaling via CRMP2 protein, which contains as an active ingredient a signal transduction regulator via Gm1 protein according to item 6 (hereinafter sometimes referred to as the drug of the present invention).
  • FIG. 1 is a diagram showing the results of Western blotting with an anti-CRMP2 antibody of a two-dimensional electrophoresis sample.
  • the upper diagram shows the results for the control cells that express the CRMP2 protein and does not express the activated Gm1 protein, and the lower diagram shows the results for the cells that co-express the CRMP2 protein and the activated Gm1 protein.
  • FIG. 2 is a diagram showing the results of quantifying each spot of the Western blot shown in FIG. The intensity of each phosphorylated CRMP2 protein spot when the intensity of the non-phosphorylated CRMP2 protein spot (No. 1) is “1” is shown.
  • FIG. 3 is a diagram showing the results of Western blotting with an anti-CRMP2 antibody of a two-dimensional electrophoresis sample.
  • the upper graph shows the results for the control (DMSO), and the lower graph shows the results using SKF81297 as the test substance.
  • FIG. 4 is a diagram showing the results of quantifying each spot of the Western blot shown in FIG. The intensity of each phosphorylated CRMP2 protein spot when the intensity of the non-phosphorylated CRMP2 protein spot (No. 1) is “1” is shown.
  • the black bar graph is the result for the control (DMSO), and the white bar graph is the result using SKF81297 as the test substance.
  • FIG. 5 is a diagram showing the results of comparing the quantitative values of each spot shown in FIG. 4 between the solvent control and the test substance.
  • the black bar graph is the result for the control (DMSO), and the white bar graph is the result using SKF81297 as the test substance.
  • Gm1 protein in the present invention is a G-protein ⁇ known to be involved in intracellular signal transduction by G-protein coupled receptor (GPCR) stimulation.
  • GPCR G-protein coupled receptor
  • the Gm1 protein is a kind of G-protein ⁇ subunit represented by the registration number “NM — 182978” in the NCBI database. Both guanine nucleotide binding protein (G protein), alpha activating lipid ligand, olfactory ligand, The N-terminal region has a characteristic structure that is about 80 amino acids longer than other G proteins.
  • the Gm1 gene is a Splicing variant of the Golf gene, and has a unique base sequence only in the first exon region, and shares the base sequence with the Golf gene after the second exon region.
  • Examples of the base sequence encoding the amino acid sequence of the Gm1 protein include the base sequence represented by SEQ ID NO: 2, 27 or 28 described in the above-mentioned publication.
  • the amino acid sequence shown by SEQ ID NO: 1 is shown in SEQ ID NO: 1
  • the base sequence shown by SEQ ID NO: 2 is shown in SEQ ID NO: 2.
  • the “Gm1 protein” in the present invention includes a part thereof as long as the biological function of the protein is maintained.
  • the amino acid sequence represented by SEQ ID NO: 1 described in the above publication has sequence identity with the amino acid sequences of “GTP binding site” and “GTPase activation site” conserved among G protein ⁇ subunits.
  • These portions are the regions of amino acid numbers 126 to 133, 287 to 292, 353 to 359, and 428 to 435 in the amino acid sequence represented by SEQ ID NO: 1 described in the publication. These amino acid regions are amino acid sequences of “GTP binding site” and “GTPase activation site” in “Gs” and “Golf” that have already been identified as G protein ⁇ subunits (NATURE, 117-127 (1991), vol.349).
  • the amino acid sequence represented by SEQ ID NO: 1 is the same as the characteristic sequence highly conserved among “Gs” and “Golf” belonging to the Gs family among G protein ⁇ subunits (shown by SEQ ID NO: 1).
  • This sequence has amino acid numbers 119 to 126) and can take an ⁇ -helical structure conserved between G protein ⁇ subunits.
  • An index indicating how many amino acid residues of the Gm1 protein can be substituted, deleted, or added without losing the biological function of the Gm1 protein should be found by the method described in JP-A-2003-193330, etc. Can do.
  • the modification that does not lose the biological function may be performed, for example, on a portion having low sequence identity with the amino acid sequences of various G protein ⁇ subunits that have already been identified. Examples of the “Gm1 protein” include proteins described in US2009-0042789.
  • CRMP2 protein in the present invention is collapsin response mediator protein 2, CRMP2, and is a factor that mediates information on semaphorin, which is a nerve guidance factor.
  • CRMP2 protein is a known protein described in, for example, Goshima et al., Nature (1995), 376, 509-514. Examples of the amino acid sequence possessed by CRMP2 protein and the base sequence encoding the amino acid sequence include the amino acid sequences and base sequences described in the above documents.
  • the CRMP2 protein is a protein represented by the registration number “NP — 001377” in the NCBI database, and is sometimes called dihydropyrimidinase-like 2, dihydropyrimidinase-like 2, or DPYSL2.
  • the transformant of the present invention is obtained by introducing both of the following genes (1) and (2) into a host cell: (1) a foreign gene having a base sequence encoding the amino acid sequence of Gm1 protein protein, and (2) a foreign gene having a base sequence encoding the amino acid sequence of CRMP2 protein protein.
  • the transformant of the present invention is a transformed cell containing a polynucleotide having a base sequence encoding the amino acid sequence of Gm1 protein protein and a polynucleotide having a base sequence encoding the amino acid sequence of CRMP2 protein protein.
  • the host cell of the transformant of the present invention any known host cell can be used.
  • bacteria such as Escherichia coli (for example, K12), Bacillus bacteria (for example, MI114), yeast (for example, AH22) Etc.), insect cells (eg, Sf cells, etc.), animal cells (eg, COS7 cells, etc.), and the like.
  • the transformant of the present invention contains a nucleic acid in the form of a plasmid containing a base sequence encoding the amino acid sequence of Gm1 protein and a base sequence encoding the amino acid sequence of CRMP2 protein for such a host cell. It can be prepared by performing an artificial operation to introduce both nucleic acids in the form of plasmids to be introduced exogenously.
  • the transformant of the present invention is subjected to an artificial operation for exogenously introducing a nucleic acid in the form of a plasmid containing both the base sequence encoding the amino acid sequence of Gm1 protein and the base sequence encoding the amino acid sequence of CRMP2 protein.
  • an artificial operation for exogenously introducing a nucleic acid in the form of a plasmid containing both the base sequence encoding the amino acid sequence of Gm1 protein and the base sequence encoding the amino acid sequence of CRMP2 protein.
  • an artificial operation a normal genetic engineering technique corresponding to the host cell to be used may be used. Specifically, for example, a commercially available transfection reagent can be used according to the method described in the instructions attached to the reagent.
  • the nucleic acid which is the form of a plasmid as a foreign gene the calcium phosphate method, the electroporation method, the lipofection method, the DEAE dextran method etc.
  • examples of the “plasmid” include a plasmid capable of co-expressing both Gm1 protein and CRMP2 protein in a host cell.
  • a plasmid is prepared according to a conventional genetic engineering technique, in which both a nucleic acid containing a base sequence encoding the amino acid sequence of the Gm1 protein and a nucleic acid containing a base sequence encoding the amino acid sequence of the CRMP2 protein are respectively present. It can be prepared by linking to a position where expression is possible downstream of the promoter of a known expression plasmid.
  • examples of the “expression plasmid” include pBR322, pUC12, pUC119, pBluescript, etc.
  • the foreign gene having the base sequence encoding the amino acid sequence of Gm1 protein and the foreign gene having the base sequence encoding the amino acid sequence of CRMP2 protein are temporarily retained in the host cell. It may be made, or may be stably held.
  • the transformant in which the foreign gene is stably retained is an indicator of a selection marker such as a drug resistance marker (for example, a drug resistance marker contained in an expression plasmid) introduced into the host cell simultaneously with the foreign gene. You can make a selection.
  • a selection marker such as a drug resistance marker (for example, a drug resistance marker contained in an expression plasmid) introduced into the host cell simultaneously with the foreign gene. You can make a selection.
  • the transformant of the present invention may be cultured in a culture solution.
  • the culture conditions for the transformant of the present invention may be appropriately selected according to the type of the transformant of the present invention.
  • the transformant of the present invention when the transformant of the present invention is a microorganism, it may be cultured using a liquid medium or a plate medium usually used for culturing microorganisms.
  • the culture temperature only needs to be within the temperature at which microorganisms can grow, and examples thereof include about 15 to 40 ° C.
  • the pH of the medium may be within the range in which microorganisms can grow, and examples thereof include about pH 6 to 8.
  • the culture time varies depending on other culture conditions, but is usually about 1 to 5 days, particularly about 1 to 2 days. When an induction type expression plasmid such as a temperature shift type or an IPTG induction type is used, the induction time may be within one day, particularly about several hours.
  • culture conditions suitable for the type of insect cell may be used.
  • the culture may be performed using an insect cell medium such as Grace's medium containing FBS and yeast.
  • the culture temperature can be about 25 to 35 ° C.
  • the pH of the medium may be within the range in which insect cells can grow, and examples thereof include about pH 6-8.
  • the culture time varies depending on other culture conditions, it is usually about 1 to 5 days, particularly about 2 to 3 days.
  • the culture time is preferably set until the cytoplasmic effect appears and the cells die (for example, about 3 to 7 days, particularly about 4 to 6 days).
  • the transformant is a mammalian cell
  • culture conditions suitable for the type of mammalian cell may be used.
  • a DMEM medium (Nissui, etc.) supplemented with FBS may be used in the presence of 5% CO 2 while being replaced with a new medium every few days.
  • FBS fetal bovine serum
  • the culture temperature can be about 36 to 38 ° C.
  • the pH of the medium may be within the range in which mammalian cells can grow, and examples thereof include about pH 6-8.
  • the culture time varies depending on other culture conditions, but is usually about 2 to 5 days, particularly about 2 to 3 days.
  • an ordinary protein engineering method may be used as a method for confirming that both Gm1 protein and CRMP2 protein are co-expressed in the cells of the transformant of the present invention.
  • an ordinary protein engineering method may be used. Specific examples include a method in which a protein extract prepared from the transformant of the present invention is subjected to Western blotting using an anti-Gm1 protein antibody and an anti-CRMP2 protein antibody.
  • the screening method of the present invention comprises (a) a first step in which a test substance is brought into contact with the transformant described in the preceding item 1, 2 or 3, and (b) phosphorylation of CRMP2 protein in the transformant after the first step.
  • test substance in the screening method of the present invention is not particularly limited, and examples thereof include proteins (including antibodies), peptides, non-peptidic compounds (nucleotides, amines, carbohydrates, lipids, etc.), organic low molecular compounds, inorganic Examples thereof include low molecular weight compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts and the like.
  • the form of the test substance is not particularly limited, and examples thereof include a solid, a liquid, a mixture with a base, a suspension or a solution.
  • a suspension or solution water, pH buffer solution, methylcellulose solution, physiological saline, organic solvent aqueous solution (ethanol or dimethyl sulfoxide is usually used as the organic solvent) and the like may be used.
  • the contact amount, the number of times of contact, and the contact time of the test substance may be set within a range that does not seriously affect the transformant of the present invention, for example.
  • the “contact” in the first step of the screening method of the present invention can be performed by a method widely used by those skilled in the art.
  • the contact method is not particularly limited.
  • the concentration is about 0.001 to 10 ⁇ M in a culture solution / agar medium containing the transformant of the present invention.
  • the test substance may be added so that In the second step of the screening method of the present invention, the “measurement of the phosphorylation state of CRMP2 protein or an index value correlated therewith” comprises the preparation of a protein extract, electrophoresis, transcription onto a membrane, detection of CRMP2 protein A method or the like can be used.
  • analysis may be performed using a normal biochemical technique, protein engineering technique, or the like. For example, it may be performed by combining two-dimensional electrophoresis and Western blotting.
  • a protein extract is first prepared from the transformant of the present invention in contact with a test substance.
  • the prepared protein extract is subjected to the first dimension electrophoresis and then the second dimension electrophoresis. Transfer the separated CRMP2 protein onto a suitable membrane.
  • the CRMP2 protein transferred onto the membrane is detected with an anti-CRMP2 protein antibody or the like.
  • CRMP2 protein is separated according to the degree of phosphorylation. Non-phosphorylated CRMP2 is detected on the more alkaline side, and phosphorylated CRMP2 is detected on the more acidic side as the degree of phosphorylation increases.
  • Separation of CRMP2 based on the degree of phosphorylation can be performed according to a commonly used method known per se.
  • a known quantification method may be used.
  • a signal detected by Western blot may be quantified with an image analyzer or the like.
  • the spot intensity of non-phosphorylated CRMP2 in the CRMP2 spot detected by Western blot after two-dimensional electrophoresis in the transformant of the present invention is “1”, and each spot of phosphorylated CRMP2 Calculate the intensity.
  • the spot intensity of the non-phosphorylated CRMP2 is “1”, and the spot intensity of each phosphorylated CRMP2 is calculated.
  • the phosphorylation state measured in the second step of CRMP2 protein in the transformant of the present invention contacted with the test substance or an index value correlated therewith, What is necessary is just to compare with the phosphorylation state measured at the 2nd process of CRMP2 protein in the transformant of this invention which is not contacting the test substance, or the index value correlated with it.
  • the “transformant of the present invention not in contact with the test substance” may be, for example, the transformant of the present invention in which only the solvent is contacted.
  • a control may be obtained by measuring the phosphorylation state of CRMP2 protein as a control or an index value correlated therewith in parallel with the phosphorylation state of CRMP2 protein in the transformant of the present invention or an index value correlated therewith.
  • it may be determined by measuring separately.
  • the measured value of the CRMP2 protein phosphorylation state in the transformant of the present invention brought into contact with the test substance or an index value correlated therewith correlates with the phosphorylation state of CRMP2 protein in the control transformant of the present invention.
  • each spot in the control is defined as 100%, and the percentage of each spot of CRMP2 detected by the transformant of the present invention in contact with the test substance is calculated.
  • a test substance in which one of the percentages of each spot of CRMP2 detected in the transformant of the present invention contacted with the test substance is, for example, 70% or less, preferably 60% or less, more preferably 50% or less May be selected as a candidate substance for a signal transduction regulator.
  • a test substance in which the percentage of the spot is, for example, 70% or less, preferably 60% or less, more preferably 50% or less is selected as a candidate for activating signal transduction. What is necessary is just to select as a substance.
  • a positive control or negative control that can be a “control substance” instead of the test substance, the above-mentioned control can be used as the case may be.
  • positive control represents any substance having an effect of controlling the phosphorylation state of CRMP2 protein
  • negative control includes a solvent contained in the test substance, a test system solution serving as a background, etc. Is mentioned.
  • the “control substance” is a negative control
  • the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the test substance is greater than the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the control substance, What is necessary is just to evaluate that the said test substance has "the effect which suppresses the phosphorylation state of CRMP2 protein.”
  • the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the test substance is similar to or smaller than the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the control substance, “CRMP2 It can be evaluated that it does not have an “effect of suppressing the phosphorylation state of a protein”.
  • the control substance When the control substance is used as a positive control, compare the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the test substance with the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the control substance. Thus, the “effect of suppressing the phosphorylation state of CRMP2 protein” possessed by the test substance may be evaluated. Thus, when it is evaluated that it has an effect, the said to-be-tested substance can be selected as a signal transduction regulator via Gm1.
  • the drug of the present invention contains, for example, the “signal transduction modulator via Gm1 protein” selected as described above as an active ingredient.
  • the agent of the present invention is useful as a therapeutic or prophylactic agent for diseases caused by abnormal signaling through the CRMP2 protein.
  • Example 1 Inhibition of CRMP2 phosphorylation by activated Gm1
  • the obtained DNA fragment was subjected to agarose gel electrophoresis, then a band of about 1.5 kb detected on the gel was cut out, DNA was recovered from the cut out gel, and the DNA was pCR2.1-TOPO vector (manufactured by Invitrogen). To pCR-Gm1.
  • the PCR conditions were 30 cycles of 95 ° C. for 30 seconds, 60 ° C. for 30 seconds, and then 72 ° C. for 2 minutes.
  • a band of about 1.5 kb detected on the gel was excised, DNA was recovered from the excised gel, and the DNA was cloned into a pDrive vector (Q1AGEN).
  • pDr-AFGm1 was produced.
  • this DNA fragment was subjected to agarose gel electrophoresis, a band of about 1.5 kb detected on the gel was excised, and DNA was excised from the excised gel.
  • Plasmid pcDNA-AFGm1 was prepared by ligating pcDNA3.1 (manufactured by Invitrogen) with EcoRV and XbaI as a vector and ligating the insert DNA with ligase.
  • the cells prepared in (5) above were used as test cells in the following tests.
  • the cells prepared in (5) above were lysed using a PhosphoProtein Purification kit (Qiagen) after the medium was removed to obtain a cell extract.
  • a protein extract (purified protein) was prepared from the cell extract using 2-D Clean-Up kit (GE Health Science).
  • the obtained protein extract 800 ⁇ g of purified protein was subjected to first-dimensional electrophoresis using Immobiline DryStripe (GE Health Science). Next, second-dimensional electrophoresis was performed using 7.5% SDS-PAGE gel.
  • the intensity of the phosphorylated CRMP2 protein spot was calculated when the intensity of the non-phosphorylated CRMP2 protein spot was “1” (see FIG. 2).
  • the signal intensity of the phosphorylated CRMP2 protein spots spots No. 2 to No. 6 in the cells in which the activated Gm1 protein was co-expressed was determined to be the activated Gm1 protein. Decreased compared to the signal intensity of the phosphorylated CRMP2 protein spot in control cells not co-expressing. From the above results, it was confirmed that activation of the Gm1 protein suppresses phosphorylation of the CRMP2 protein.
  • Example 2 (Screening method of the present invention: screening of a signal transduction regulator through Gm1 protein) (Part 1) (1) Construction of pcDNA-Gm1
  • the plasmid pCR-Gm1 prepared in Example 1 was double digested with restriction enzymes XbaI and KpnI using a method according to the method described in the literature (Japanese Patent Laid-Open No. 2004-350672). Thereafter, this DNA fragment was subjected to agarose gel electrophoresis, a band of about 1.5 kb detected on the gel was cut out, DNA was recovered from the cut out gel, and the DNA was used as insert DNA.
  • a plasmid pcDNA-Gm1 was prepared by ligating pcDNA3.1 (manufactured by Invitrogen) with XbaI and KpnI as a vector and ligating the insert DNA with ligase.
  • COS7 cells purchased from ATCC
  • DMEM medium manufactured by Invitrogen
  • the obtained culture After being added to the cell culture medium, the obtained culture was allowed to stand at 37 ° C. for 30 minutes. Next, after removing the medium containing SKF81297 from the obtained culture, the cell extract was obtained by lysis using PhosphoProtein Purification kit (Qiagen). A protein extract (purified protein) was prepared from the cell extract using 2-D Clean-Up kit (GE Health Science). As a control, a culture in which only the DMSO solvent was added to the cell culture medium instead of SKF81297 was prepared, and a protein extract (purified protein) was prepared in the same manner. The obtained protein extract (800 ⁇ g of purified protein) was subjected to first-dimensional electrophoresis using Immobiline DryStripe (GE Health Science).
  • the spot located on the 6 side is a CRMP2 protein spot with a higher degree of phosphorylation.
  • the signal intensity of each spot detected by the Western blot shown in FIG. 3 was measured using LAS-4000 (Fuji Film).
  • the intensity of the phosphorylated CRMP2 protein spot was calculated when the intensity of the non-phosphorylated CRMP2 protein spot was “1” (see FIG. 4).
  • the signal intensity of the “higher phosphorylated spots (spots No. 6 and No. 5)” in the cells contacted with SKF81297 was contacted only with DMSO solvent. In comparison with the signal intensity of “higher phosphorylated spots (spots No. 6 and No. 5)” in the cells.
  • the signal intensity of “spots with low phosphorylation (spots No. 2 and No. 3)” in cells contacted with SKF81297 is “spot with low phosphorylation” in cells contacted only with DMSO solvent. (Spot No. 2 and No. 3) ”and increased. From the above results, in the cells contacted with SKF81297, as a result of the suppression of the degree of phosphorylation, CRMP2 protein in a more highly phosphorylated state decreased, and accordingly, the CRMP2 protein having a low degree of phosphorylation It was confirmed that the amount increased relatively.
  • Example 3 screening method of the present invention: screening of a signal transduction regulator through Gm1 protein) (Part 2) COS7 cells (purchased from ATCC) were seeded in a 10 cm petri dish at 5 ⁇ 10 6 cells / petri dish, and about 10% FCS-containing DMEM medium (manufactured by Invitrogen) under conditions of 37 ° C. and 5% CO 2. Incubate for 24 hours. Both “Gm1 expression plasmid (pcDNA-Gm1; 12 ⁇ g)” obtained in (7) above and “CRMP2 expression plasmid (pcDNA-CRMP2; 6 ⁇ g)” obtained in (3) above were combined with 45 ⁇ l of lipoprotein.
  • the cells are mixed with Perfectamine 2000 (Invitrogen) and kept for 20 minutes to transfect the cells.
  • the medium is completely changed 3 hours after transfection, and further cultured for about 21 hours.
  • various test substances are added to the cell culture solution so as to have a final concentration of 10 ⁇ M, and the obtained culture is allowed to stand at 37 ° C. for 30 minutes.
  • a cell extract is obtained by lysis using a PhosphoProtein Purification kit (Qiagen), and then 2-D Clean from the cell extract.
  • -A protein extract purified protein
  • Up kit GE Health Science
  • a culture in which only the DMSO solvent is added to the cell culture medium instead of the test substance is prepared, and a protein extract (purified protein) is prepared in the same manner.
  • the obtained protein extract 800 ⁇ g of purified protein
  • second-dimensional electrophoresis is performed using 7.5% SDS-PAGE gel.
  • the gel after two-dimensional electrophoresis is transferred to Hybond-P (GE Health Science).
  • the CRMP2 protein transferred onto the membrane is detected by Western blotting using an anti-CRMP2 antibody (C4G) (Immuno-Biological Laboratories, Inc.).
  • the signal intensity of each spot detected by Western blotting was measured using LAS-4000 (Fuji Film).
  • the intensity of the phosphorylated CRMP2 protein spot is calculated when the intensity of the non-phosphorylated CRMP2 protein spot is “1”.
  • the value of each spot in the cells contacted only with DMSO solvent is set to 100%, and the value of each spot in the cells contacted with the test substance is determined. Calculate the percentage.
  • the test substance in which the percentage of the spot signal is 50% or less is defined as a “signal transduction modulator via Gm1 protein”.
  • a drug containing the selected “signal transduction modulator via Gm1 protein” as an active ingredient that is, a therapeutic or prophylactic agent for a disease caused by abnormal signal transduction via CRMP2 protein
  • the present invention it is possible to provide a screening method for a signal transduction regulator through Gm1 protein, a test tool including a transformant used for the screening method, and the like.
  • Oligonucleotide primer designed for PCR SEQ ID NO: 3 Oligonucleotide primer designed for PCR SEQ ID NO: 4
  • Oligonucleotide primer designed for PCR SEQ ID NO: 5 Oligonucleotide primer designed for PCR SEQ ID NO: 6
  • Oligonucleotide primer designed for PCR SEQ ID NO: 7 Oligonucleotide primer designed for PCR SEQ ID NO: 8
  • Oligonucleotide primer designed for PCR SEQ ID NO: 9 Oligonucleotide primer designed for PCR SEQ ID NO: 10
  • Oligonucleotide primers designed for PCR SEQ ID NO: 10 Oligonucleotide primers designed for PCR

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne : un transformant qui est obtenu par introduction d'un gène Gm1 et d'un gène CRMP2; un procédé de criblage pour une substance modulatrice de la signalisation médiée par une protéine Gm1, ledit procédé utilisant le transformant; et similaire.
PCT/JP2011/065918 2010-07-07 2011-07-06 Transformant obtenu par introduction d'un gène gm1 et d'un gène crmp2 WO2012005379A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010154527A JP2012016303A (ja) 2010-07-07 2010-07-07 Ｇｍ１遺伝子及びＣＲＭＰ２遺伝子が導入されて得られる形質転換体並びにその利用
JP2010-154527 2010-07-07

Publications (1)

Publication Number Publication Date
WO2012005379A1 true WO2012005379A1 (fr) 2012-01-12

Family

ID=45441347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/065918 WO2012005379A1 (fr) 2010-07-07 2011-07-06 Transformant obtenu par introduction d'un gène gm1 et d'un gène crmp2

Country Status (2)

Country Link
JP (1) JP2012016303A (fr)
WO (1) WO2012005379A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012108548A1 (fr) * 2011-02-10 2012-08-16 住友化学株式会社 TRANSFORMÉ DANS LEQUEL ONT ÉTÉ INTRODUITS LE GÈNE Gm1, LE GÈNE GPCR, ET LE GÈNE CRMP2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004350672A (ja) * 2002-07-16 2004-12-16 Sumitomo Chem Co Ltd 新規ｇ−タンパク質及びその利用
JP2006288387A (ja) * 2005-03-15 2006-10-26 Sumitomo Chemical Co Ltd 気分障害又は関連障害による疾患症状を改善させる方法
JP2006320201A (ja) * 2005-05-17 2006-11-30 Sumitomo Chemical Co Ltd 気分障害又は関連障害による疾患症状を改善させる方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004350672A (ja) * 2002-07-16 2004-12-16 Sumitomo Chem Co Ltd 新規ｇ−タンパク質及びその利用
JP2006288387A (ja) * 2005-03-15 2006-10-26 Sumitomo Chemical Co Ltd 気分障害又は関連障害による疾患症状を改善させる方法
JP2006320201A (ja) * 2005-05-17 2006-11-30 Sumitomo Chemical Co Ltd 気分障害又は関連障害による疾患症状を改善させる方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARAI M. ET AL.: "A hard road in psychiatric genetics: schizophrenia and DPYSL2.", JOURNAL OF HUMAN GENETICS, vol. 55, no. 7, 3 June 2010 (2010-06-03), pages 397 - 399 *
CORRADI J.P ET AL.: "Alternative transcripts and evidence of imprinting of GNAL on 18pll.2.", MOLECULAR PSYCHIATRY, vol. 10, no. 11, 2005, pages 1017 - 1025, XP009115009, DOI: doi:10.1038/sj.mp.4001713 *
GOSHIMA Y. ET AL.: "Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33.", NATURE, vol. 376, no. 6540, 1995, pages 509 - 514, XP002913365, DOI: doi:10.1038/376509a0 *
NAKATA K. ET AL.: "The human dihydropyrimidinase- related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia.", BIOLOGICAL PSYCHIATRY, vol. 53, no. 7, 2003, pages 571 - 576 *
YOSHIMURA T. ET AL.: "Molecular Mechanisms of Axon Specification and Neuronal Disorders.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1086, November 2006 (2006-11-01), pages 116 - 125 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012108548A1 (fr) * 2011-02-10 2012-08-16 住友化学株式会社 TRANSFORMÉ DANS LEQUEL ONT ÉTÉ INTRODUITS LE GÈNE Gm1, LE GÈNE GPCR, ET LE GÈNE CRMP2

Also Published As

Publication number Publication date
JP2012016303A (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
Kim et al. Structural requirements for VAP-B oligomerization and their implication in amyotrophic lateral sclerosis-associated VAP-B (P56S) neurotoxicity
WO1998038217A1 (fr) Recepteurs de serotonine actives par constitution
Song et al. Nucleocytoplasmic shuttling of valosin-containing protein (VCP/p97) regulated by its N domain and C-terminal region
EP3491014B1 (fr) Amorce ou sonde allèle-spécifique hybridée à une molécule d'acide nucléique codant pour un variant gpr156
JP5328190B2 (ja) Ｔｒｐａ１の活性化物質の評価方法
JP2019129772A (ja) ２−ヘプタノンの匂いを抑制する物質のスクリーニング方法
JP2019129773A (ja) ２−ノナノンの匂いを抑制する物質のスクリーニング方法
WO2012005379A1 (fr) Transformant obtenu par introduction d'un gène gm1 et d'un gène crmp2
US7070940B2 (en) Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein
WO2012108548A1 (fr) TRANSFORMÉ DANS LEQUEL ONT ÉTÉ INTRODUITS LE GÈNE Gm1, LE GÈNE GPCR, ET LE GÈNE CRMP2
US20090165151A1 (en) Canine transient receptor potential v2 (ctrpv2) and methods of screening for trpv2 channel modulators
TW202221013A (zh) 突變型昆蟲嗅覺受體蛋白質
US6780600B2 (en) Synaptic activation protein compositions and method
Xu et al. Identification of Rgl3 as a potential binding partner for Rap-family small G-proteins and profilin II
JP2019010058A (ja) フェノリック香料素材のスクリーニング方法
US7425614B2 (en) Neuroprotective therapeutics preventing ERK/MAPK activation through the NMDA receptor
Pawlikowski et al. Formation of complex AChR aggregates in vitro requires α‐dystrobrevin
JP2014054218A (ja) 忌避剤候補物質のスクリーニング方法
US20100160217A1 (en) Acetylycholine gated ion channel chaperons and methods of using the same
Beitia Regulation of Wnt signalling pathways by the Dishevelled DEP domain
JP2013068558A (ja) Ｇｍ１遺伝子が導入されて得られる形質転換体の利用
JP2013066445A (ja) Ｇｍ１遺伝子及びｐ２７遺伝子が導入されて得られる形質転換体並びにその利用
JP2022059100A (ja) ナトリウムの作用を調節する物質のスクリーニング方法
JP7556688B2 (ja) Ｇｐｒ１５６変異体及びその使用
Hussein Functional Characterization of the TRP-Type Channel PKD2L1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11803709

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11803709

Country of ref document: EP

Kind code of ref document: A1